Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein

@inproceedings{Tian2017StructuralBO,
  title={Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein},
  author={Daiyin Tian and Michael B Battles and Syed M. Moin and Man Chen and Kayvon Modjarrad and Azad Kumar and Masaru Kanekiyo and Kevin W. Graepel and Noor M Taher and Anne L. Hotard and Martin L Moore and Min Zhao and Zi-Zheng Zheng and Ningshao Xia and Jason S McLellan and Barney S. Graham},
  booktitle={Nature Communications},
  year={2017}
}
A licensed vaccine for respiratory syncytial virus (RSV) is unavailable, and passive prophylaxis with the antibody palivizumab is restricted to high-risk infants. Recently isolated antibodies 5C4 and D25 are substantially more potent than palivizumab, and a derivative of D25 is in clinical trials. Here we show that unlike D25, 5C4 preferentially neutralizes subtype A viruses. The crystal structure of 5C4 bound to the RSV fusion (F) protein reveals that the overall binding mode of 5C4 is similar… CONTINUE READING

From This Paper

Figures and tables from this paper.

References

Publications referenced by this paper.
Showing 1-10 of 43 references

Epitope of rsv fusion protein and antibody recognizing the same

Zheng, Z Z.
United States patent • 2016

How good are my data and what is the resolution?

Acta crystallographica. Section D, Biological crystallography • 2013

Similar Papers

Loading similar papers…